NGIVD has been promoted by individual entrepreneurs with extensive background in healthcare, diagnostics, service industry and fund management. NGIVD is developing novel diagnostics tests for Infectious disease diagnosis based on molecular diagnostics and microfluidics platforms. Its product portfolio includes LAMP test for Tuberculosis (WHO recommended) through exclusive partnership with Human GmbH, Novel diagnostic kit for Cervical Cancer Screening and RU-1: A Multiplex bead based serological diagnostic test for Pulmonary, Extra Pulmonary and Pediatric Tuberculosis, undergoing Phase 3 trials in India. It has other products also in pipeline like LAMP Test for diagnosis of VL and PKDL Leishmaniasis – technology licensed from ICMR, Multiplex Panels for diagnosis of Fever, Blood Screening, etc. All the proposed products / technologies are highly disruptive and have the potential to address the bottom-of-the-pyramid healthcare needs in emerging economies.